News | August 02, 2021
Glenmark signs agreement with SaNOtize to manufacture NONS
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Sumatriptan Injection USP is indicated in adults for acute treatment of migraine with or without aura, and acute treatment of cluster headache
The company has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from USFDA
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Subscribe To Our Newsletter & Stay Updated
